nejm semaglutide cardiovascular Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential clinicaltrials #medicalresearch | NEJM Group

To view or add a comment, sign in FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes

Namely, pigmentation changes may continue beyond the active presence of the peptide itself

Liraglutide is much shorter, around 13 hours, so it is dosed once daily

The metered spray delivery system allows researchers to administer controlled quantities during experimental applications where precise measurement is required

Comparison to Other Senolytic Therapies To contextualise FOXO4-DRI, lets compare it to other senolytic approaches or peptides you may be aware of (helpful given your clinics peptide focus)

Instead, it activates the GH secretagogue receptor 1a (GHSR1a), the same receptor that the natural hormone ghrelin binds to